News >

Treosulfan Conditioning Regimen for Allogeneic HSCT Improves Survival for MAC-Ineligible AML, MDS

Virginia Powers, PhD
Published: Wednesday, Mar 27, 2019

Dietrich Beelen, MD, PhD

Dietrich Beelen, MD, PhD

Treosulfan added to fludarabine demonstrated an improvement in event-free and overall survival (OS) compared with busulfan/fludarabine as a treatment for patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) who are scheduled for allogeneic hematopoietic stem cell transplantation (HSCT) but are considered ineligible for standard myeloablative conditioning (MAC), according to phase III findings presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x